Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.55 +2.25%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
MTEX, NSYS, PLNH, More
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
MTEX, NSYS, PLNH, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.
The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
- Southland Holdings (SLND) Misses Q2 EPS by 122c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
